



2023

Convenors: Barnaby Reeves, Beverley Shea, George Wells, Hugh Sharma Waddington



Highlight:

Developing author guidance on NRSIs implications in Cochrane Reviews and supporting global capacity to determine study inclusion, bias assessment and effect size calculation



Research and development

- Development of a tool to assess the methodological quality of systematic reviews incorporating Diagnostic Test Accuracy (DTA) studies (AMSTAR 2-DTA), supported by a grant from the Canadian Institutes of Health Research (CIHR).
- Further development of risk of bias approaches consistent with [ROBINS-I](#) for the appraisal of NRSI used in public health and social science, including regression discontinuity, differences and matched designs.
- Developing approaches for identifying [confounders in NRSI](#) and meta-analysis of existing data to measure rare outcomes using study participant flows reported in trials and NRSI.



Best practice and guidance

- Contributing to the development of Cochrane author guidance on the incorporation of NRSI in systematic reviews, involving collaboration with the GRADE Methods Group and Campbell Study Design and Bias Assessment Group, supported by a Cochrane Methods Grant.



Methods implementation

- Supporting a collaboration with researcher partner organisations in low- and middle-income countries (Bangladesh, Ghana, India, Philippines and Uganda) to collect effect size data from RCTs and NRSI of 1,700 studies of interventions to reduce child involvement in violent offending, supported by a grant from the Youth Endowment Fund.
- Support for ROBINS-I workshop at [2023 Cochrane Colloquium](#).